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. Furthermore, electrophoretic gel mobility shift analysis of cPLA 2 -a on SDS-PAGE demonstrated a PCB-dependent phosphorylation of cPLA 2 -a. The effects of 17b-estradiol and two structurally unrelated antiestrogens, nafoxidin and tamoxifen on PCB-induced arachidonic acid release in platelets were also investigated. Both nafoxidin and tamoxifen inhibited PCB-induced arachidonic acid release as well as 12-HETE and 12-HHT formation. Interestingly, platelets incubated with PCBs did not aggregate despite the fact that robust release of arachidonic acid was observed. In summary, these results demonstrate that certain PCBs induce activation of cPLA 2 -a independent of a rise in intracellular calcium and a robust release of arachidonic acid release with resulting eicosanoid formation in human platelets.
# 2005 Elsevier Inc. All rights reserved.
Introduction
Phospholipase A 2 (PLA 2 ) enzymes catalyze the hydrolysis of the sn-2 ester bond in phospholipids and hence, the release of a free fatty acid [1] . PLA 2 enzymes are a diverse family consisting of at least 16 different enzymes [2] . The intracellular group IV cytosolic PLA 2 -a (cPLA 2 ) [3, 4] has attracted much interest in the biosynthesis of eicosanoids since it preferentially release arachidonic acid from membrane phospholipids. Interestingly, macrophages from mice deficient in cPLA 2 -a produced no prostaglandins or leukotrienes and various disease models have now been studied in these animals [5] . These mice demonstrate reduced fertility and reduced brain injury after cerebral ischaemia [6] [7] [8] . Three human paralogs of the cPLA 2 -a enzyme have also been identified, termed cPLA 2 -b, cPLA 2 -g and cPLA 2 -d [9] [10] [11] . Crystallographic studies of cPLA 2 -a demonstrated the presence of two domains, an N-terminal calcium-phospholipid-binding (C2) domain and a catalytic domain [12] . Calcium promotes cytosol-to-membrane relocation of the cPLA 2 -a protein by binding to the C2-domain [13] [14] [15] . However, cPLA 2 -a targeting to membranes by calcium ions is complex since it is dependent both on the amplitude and the duration of the calcium increase [16, 17] . The catalytic domain can affect membrane association of the enzyme by modulating the rate of association and also the residence time at membranes [18] . Furthermore, there is now convincing evidence that calcium-independent pathways for cytosol-tomembrane translocation of cPLA 2 -a exists [19] [20] [21] [22] [23] [24] , thus, suggesting alternative mechanisms for membrane association. One such mechanism could involve calcium-independent association of cPLA 2 -a to anionic phospholipids [21, 24, 25] .
Phosphorylation of cPLA 2 -a has been reported in several cell types and on several amino acid residues [26, 27] . The role of phosphorylation in membrane association of cPLA 2 -a is unclear but is has been demonstrated that phosphorylation events can, at least partially, contribute to cPLA 2 -a activation [27] [28] [29] [30] .
Human platelets metabolize free arachidonic acid via cyclooxygenase/thromboxane synthase and lipoxygenase pathways. Cyclooxygenase 1 (COX1) produces prostaglandin H 2 (PGH 2 ) from arachidonic acid. PGH 2 is rearranged to thromboxane A 2 (TXA 2 ) by thromboxane A 2 synthase. Thromboxane A 2 synthase catalyzes in a parallel and almost equimolar reaction, the fragmentation of PGH 2 into 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-HHT) and malondialdehyde. Thus, the formation of 12-HHT can be used as a marker of TXA 2 synthesis. The major lipoxygenase metabolite of arachidonic acid found in platelets is 12(S)-hydroxy-5,8-cis-10-trans-14-cis-eicosatetraenoic acid (12-HETE), formed by 12-lipoxygenase (12-LO).
Polychlorinated biphenyls (PCBs) are a family of relatively chemical stabile environmental pollutants. Many of the biological effects observed for PCBs are due to their ability to mimic hormones such as thyroid and steroid hormones [31] [32] [33] . Planar PCBs congeners, i.e. non-ortho-substituted biphenyls, are high-affinity ligands for the aromatic-hydrocarbon (Ah) receptor while the non-planar PCB congeners, i.e. orthosubstituted biphenyls, display no or weak affinity for the Ahreceptor [31] . Some of the toxicity observed for PCBs involves reproductive toxicity [31] , immunotoxicity [34] , neurotoxicity [35] as well as induction of hepatic xenobiotic-metabolizing enzymes [36] . PCB exposure is also associated with a modest decrease in maternal and umbilical cord serum arachidonic acid concentrations [37] . Several reports describe cellular activation by PCBs as well as induction of arachidonic acid release from different mammalian cells including rat neutrophils, myometrial cells and neuronal cells [38] [39] [40] [41] [42] [43] [44] . In neuronal cell culture model, PCBs induce arachidonic acid release and perturbed intracellular signaling [43, 45] , suggesting a possible link between arachidonic acid metabolism and neurotoxicity. Also, PCBs increases frequency of uterine contractions possibly by a mechanism involving PLA 2 -dependent arachidonic acid release [40] . Phosphorylation events are, at least partially contributing to PCB-induced arachidonic acid release in rat neutrophils [46] .
The mechanism behind PCB-induced arachidonic acid release is still unclear. Several reports describe PCB-induced arachidonic acid release to be independent or just marginally affected by chelation of extracellular and intracellular calcium [39, 43, 44, 47] . Thus, the conclusion in several studies is that a calcium-independent PLA 2 (iPLA 2 ) is involved in PCB-induced arachidonic acid release. Despite the fact that arachidonic acid release has been observed for many cell types, few reports describe the formation of eicosanoids. In myometrial cells, less than 1% of arachidonate was converted to eicosanoids [40] , whereas in a rat neutrophil preparation approximately 18% was metabolized into TXB 2 , 12-HHT and 12-HETE, i.e. eicosanoids primarily produced by platelets [39] .
The objective of this study was to investigate if PCBs induce arachidonic acid release in human platelets and whether this fatty acid is converted into eicosanoids. With the recent supplemented with 2 mM EGTA.
Measurement of 14 C-arachidonic acid release
Human platelets were resuspended in PBS containing 50 mM acetylsalicylic acid, 100 mM NDGA and 0.25 mCi/ml 14 Harachidonic acid and incubated for 60 min at 37 8C. Thereafter, cells were centrifuged and washed thrice to remove unincorporated arachidonic acid. Labeled platelets were resuspended in PBS containing 50 mM acetylsalicylic acid, 100 mM NDGA. The samples were incubated with or without tamoxifen or nafoxidin for 10 min at 37 8C prior to the addition of 35 mM CB52 or 17b-estradiol and thereafter incubated for another period of 10 min. The reaction was terminated with one volume of methanol. The samples were thereafter stored at À20 8C and processed by solid phase extraction and analyzed by RP-HPLC as described.
2.4.
Incubation of intact platelets and broken cell assay
Human platelets in 1 ml PBS was preincubated at 37 8C for the indicated times with DMSO or inhibitor as indicated. Subsequently, PCBs or calcium ionophore A23187 was added and the samples were incubated for 10 min at 37 8C. The reaction was terminated by the addition of 1 ml methanol. Samples were stored at À20 8C until eicosanoid content was analyzed. Cells (4 Â 10 8 ) for the homogenate assay were centrifuged and resuspended in PBS (w/o Ca 2+ and Mg
2+
) supplemented with 1 mM EDTA and sonicated for 2 Â 5 s. The samples were preincubated with the indicated compounds at 37 8C for 20 min. Thereafter, 20 mM arachidonic acid was added and the samples were incubated for another 10 min before termination.
Platelet aggregation
Platelet aggregation was measured by using an aggregometer. Platelets, suspended in PBS with Ca 2+ and Mg 2+ , were incubated at 37 8C with continuous stirring, and percent light transmission was recorded using a buffer sample as blank. Aggregation was initiated by the addition of 1 mM calcium ionophore A23187 or PCBs as indicated. In some experiments, samples were incubated with PCB at 37 8C for 10 min prior to aggregometer measurements.
Measurement of intracellular Ca

2+
Platelets were incubated with 10 mM Fura2-AM for 45 min at 20 8C. The incubation mixture was occasionally gently shaken. Fura2 loaded platelets were washed twice to remove extracellular Fura2-AM. Fluorescence was measured with continuous stirring of platelets. Excitation wavelengths were 335 and 363 nm with emission wavelength set at 510 nm using a Shimadzu spectrofluorimeter.
Subcellular fractionation
Platelets (10 9 ) were incubated with vehicle or PCB for 10 min at 37 8C and subsequently centrifuged at 1000 Â g for 10 min. The pellet was resuspended in buffer A [20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 0.5 mM dithiothreitol and 10% glycerol] supplemented with 1 mM phenylmethanesulfonyl fluoride and homogenized by sonication twice for 5 s. The resulting homogenate was centrifuged at 100,000 Â g for 60 min. The 100,000 Â g supernatant was designated as cytosolic fraction; the 100,000 Â g pellet was washed once, thereafter resuspended in buffer A and sonicated to obtain the
membrane fraction. The samples were thereafter either subjected to SDS-PAGE or analysed for calcium-dependent or calcium-independent PLA 2 activity. Protein content was measured with a kit (Bio-Rad) against bovine serum albumin as the standard protein.
2.8.
Analysis of PLA 2 activity
Calcium-dependent and calcium-independent PLA 2 activity was assayed with 2 mM palmitoyl-2-[1-
14
C]-arachidonyl PtdCho and 1-palmitoyl-2-[1-
14 C]-arachidonyl PtdEtn, at a 1:1 molar ratio, as substrate. The substrates were dried under nitrogen and for measurement of calcium-dependent PLA 2 activity, resuspended in 80 mM glycine pH 9.0, 5 mM CaCl 2 , 0.5 mM DTT, 1 mg/ml albumin and 10% glycerol (vol.%). For the calcium-independent PLA 2 assay, substrates were resuspended in buffer A supplemented with 1 mg/ml albumin. These preparations were vortexed and sonicated in a water bath for 10 min at 4 8C. The reaction was initiated by adding 75 ml aliquots of sample and allowed to proceed for 60 min at 37 8C with agitation before termination by the addition of two volumes of methanol containing 0.5% acetic acid and 40 mM stearic acid.
Analysis of 12-HHT, 12-HETE and arachidonic acid
Samples were centrifuged and the resulting supernatants were applied to Sep-Pak 1 C18 cartridges (Waters associated, Milford, USA). After washing, bound compounds were eluted with 400 ml methanol. The eluates were analysed by reversephase (RP)-HPLC essentially as described [53] . Qualitative analysis was performed by comparison with retention times of authentic standards and by spectrum analysis using a diodearray spectrophotometer. Radioactivity was detected with a b-RAM HPLC flow-through monitor system (Inus System Inc., USA) coupled on-line to the HPLC.
SDS-PAGE and immunoblotting
Samples were mixed with loading buffer [50 mM Tris (pH 6.8), 10% glycerol, 0.1% SDS, 3 mM 2-mercaptoethanol and 0.005% bromophenol blue] heated for 3 min at 95 8C and loaded onto a 10% SDS-PAGE. For phosphorylation-induced electrophoretic mobility shift analysis of cPLA 2 -a, the gel was run an additional 45 min after the front had migrated out of the gel. Afterwards, the gels were subjected to immunoblotting. Briefly, the samples were transferred to Hybond TM -C nitrocellulose sheets (Amersham, UK) and thereafter blocked with 5% milk powder in Tris-buffered saline with 0.1% Tween for 60 min. Membranes were incubated over night at 4 8C with polyclonal rabbit anti-human cPLA 2 antiserum. Enhanced chemiluminescence, ECL-PLUS TM , was used for detection (Amersham, UK).
Analysis of results
Results are expressed as mean AE S.E. Statistical significance was assessed using Student's paired t-test. Inhibitory activity was analyzed using GraphPad Prism 3 and IC50-values were obtained by non-linear regression analysis.
Results
Effects of PCBs on the biosynthesis of 12-HETE and 12-HHT in intact platelets
Arachidonic acid released from platelets is rapidly converted to either 12-HETE or TXA 2 and 12-HHT [54] . Therefore, the level of free arachidonic acid is usually very low in platelets even after stimulation. To circumvent this, several investigators block the metabolism, as well as the reacylation processes, of arachidonic acid by the use of general inhibitors such as indomethacin, eicosa-5,8,11,14-tetraynoic acid (ETYA) or lipoxygenase inhibitors such as BW4AC [54, 55] . We used a similar approach and included the lipoxygenase inhibitor NDGA (50 mM) and the cyclooxygenase inhibitors indomethacin (5 mM) or acetylsalicylic acid (50 mM). Also, to avoid the use of inhibitors and thereby to get a more physiological relevant model, we measured arachidonic acid release indirectly by measuring the levels of two major metabolites of arachidonic acid in platelets, i.e. 12-HETE and 12-HHT.
To investigate if platelets release arachidonic acid after stimulation with PCBs, intact human platelets were incubated with four different isolated PCBs congeners and four former commercial PCB mixtures ( Table 1) . Two of the congeners, CB47 and CB52, induced the release of arachidonic acid and the formation of eicosanoid formation to the same extent as the calcium ionophore A23187 ( Table 1 ). The sum of the production of 12-HETE and 12-HHT was approximately 2.2-fold higher in CB52-treated platelets than in A23187-treated platelets. Also, three out of four PCB mixtures, i.e. Clophen 30, Clophen 40 and Clophen 50, induced eicosanoid formation. Interestingly, no formation of leukotrienes could be observed after incubation of human neutrophils or B-lymphocytes with PCBs, showing that PCBs are not sufficient enough stimuli to induce leukotriene formation in these cells (data not shown).
The labelling of the PCB mixtures can roughly be a measure of the degree of chlorination of the biphenyl moiety. The major constituent in the PCB products A30, A40, A50, and A60 are trichlorinated biphenyls (48%), tetra-chlorinated biphenyls (52%), penta-chlorinated biphenyls (55%) and hexa-chlorinated biphenyls (54%), respectively [52] . Further, the percentage of lowchlorinated biphenyls (tetra-chlorinated or lower) in the four PCB products A30, A40, A50, and A60, are 93%, 70%, 19%, and 1%, respectively. Thus, the observed effects (Table 1) are most pronounced after treatments with the tetra-chlorinated PCBs (CB47 and CB52) and the low-chlorinated PCB products (A30 and A40), indicating that the effects are linked to the degree of chlorination.
In order to investigate the effects of PCBs on enzyme activity in a broken cell assay, the effects of CB52 on conversion of exogenous arachidonic acid into 12-HETE and 12-HHT was determined. Homogenate samples incubated for 10 min with 35 mM (10 mg/ml) CB52 and subsequently stimulated with 20 mM arachidonic acid demonstrated a 30 AE 6.5% reduction of 12-HHT levels, as compared to vehicle treated samples. The arachidonic acid seemed to be shunted to the 12-LO pathway since the production of 12-HETE increased by 31 AE 5.7% (data is mean AE range from two separate experiments performed in duplicate). Because of its high capacity to induce arachidonic acid release and its relatively small
inhibitory effect on COX/TXA 2 pathways, CB52 was selected for further studies.
A time curve for CB52 induced 12-HETE and 12-HHT synthesis is shown in Fig. 1A . The production of 12-HETE showed a lag phase, and production reached a plateau after about 20 min. In contrast, no lag phase is seen for the production of 12-HHT.
For comparison, calcium ionophore-induced 12-HETE and 12-HHT production in human platelets is very rapid and is almost completed within 1 min (data not shown). A doseresponse curve for CB52 is shown in Fig. 1B . Half maximal response for both 12-HETE and 12-HHT formation occurred with a dose of about 35 mM CB-52.
Platelets studied by light microscopy after stimulation with CB52 revealed no gross morphological changes as compared to vehicle-treated cells (data not shown).
3.2.
PCB-induced arachidonic acid release in human platelets is mediated by cPLA 2 -a PCBs are suggested to activate two distinct PLA 2 activities, i.e. calcium-dependent and calcium-independent [39] . Therefore, we investigated the involvement of PLA 2 enzymes in PCBinduced release of arachidonic acid in human platelets. To discriminate between secretory PLA 2 (sPLA 2 ) and intracellular PLA 2 -mediated arachidonic acid release, we employed the PLA2 inhibitors pyrrolidine-1, AACOCF 3 and BEL. Pyrrolidine-1 is a potent and selective inhibitor of cPLA 2 -a [48, 49] . BEL is an inhibitor of iPLA 2 [56, 57] whereas AACOCF 3 inhibits both cPLA 2 -a and iPLA 2 [56, 58] . Furthermore, AACOCF 3 is known to inhibit thrombin-and calcium ionophore-induced arachidonic acid release and 12-HETE synthesis in human platelets [54, 59] .
Preincubation of human platelets for 10 min with increasing concentrations of pyrrolidine-1, AACOCF 3 or BEL led to decreased amounts of 12-HETE in a dose-dependent manner after stimulation with CB52 ( Fig. 2A) . Pyrrolidine-1 was approximately 150 times more potent than AACOCF 3 and displayed an IC 50 value of 38 nM. BEL demonstrated a reduction of 12-HETE synthesis by 52% at the highest dose tested (30 mM). However, the results obtained with 30 mM BEL is likely not due to a specific inhibition of iPLA 2 , since other intact cell assays demonstrate IC 50 values of less than 5 mM BEL on arachidonic acid release or eicosanoid synthesis [53, 60] . In line with this, the broken cell assay demonstrated that 30 mM BEL inhibited the conversion of exogenous arachidonic acid into 12-HETE by 42.1 AE 3.7%. AACOCF 3 at 10 mM had no effect on the formation of 12-HETE in a broken cell assay (98.6 AE 1.2% of vehicle-treated samples (data is mean AE range from two separate experiments performed in duplicate)). This is consistent with an earlier study showing that 12-HETE formation induced by addition of arachidonic acid to platelets was not blocked by AACOCF 3 [54] .
Direct measurement of arachidonic acid release was performed by using platelets labeled with [1- Platelets were incubated with the indicated PCB compound (10 mg/ml) for 10 min at 37 8C. In summary, these pharmacological results suggest a role for cPLA 2 -a in PCB-induced arachidonic acid release in human platelets.
3.3.
Effects of CB52 on cPLA 2 
-a translocation and phosphorylation
We further explored the role of cPLA 2 -a in PCB-induced arachidonic acid release by measuring PLA 2 activity as well as cPLA 2 -a and iPLA 2 protein content in platelets treated with or without CB52. Homogenate, cytosolic and membrane fractions were obtained from untreated or CB52-treated platelets. As depicted in Fig. 3A (upper panel, gray  bars) , the majority of PLA 2 activity was found in the cytosolic fraction of non-stimulated platelets. Interestingly, the PLA 2 activity translocated to the membrane fraction after stimulation of platelets with CB52 (Fig. 3A, upper  panel, black bars) . To investigate if the observed shift of PLA 2 activity from the cytosolic to the membrane fraction could be ascribed to different cPLA 2 -a content, immunoblotting was performed on these fractions. Fig. 3A (lower panel) demonstrates that cPLA 2 -a indeed translocated from the cytosolic to the membrane fraction upon CB52 treatment of intact platelets.
It is established that phosphorylation of cPLA 2 -a leads to reduced electrophoretic mobility on SDS-PAGE [61] . Interestingly, a change in the ratio between phosphorylated and unphosphorylated cPLA 2 -a protein was observed after CB52-treatment (Fig. 3A) . As seen in the two most left lanes containing control homogenate and homogenate from CB52 treated platelets, respectively, a majority of the cPLA 2 -a protein shifted its electrophoretic mobility to a slower migrating form after CB52 treatment, suggesting that the cPLA 2 -a protein became phosphorylated after CB52 treatment.
The time course of cPLA 2 -a cytosol-to-membrane translocation was investigated by Western blot analysis of platelets treated with CB52 for various times. As outlined in Fig. 3B , the cPLA 2 -a content in the membrane fraction reached a plateau The cytosol-to-membrane translocation of cPLA 2 -a correlates well with the time course for eicosanoid synthesis and the tendency to dissociation is in line with eicosanoid synthesis reaching a plateau at 20 min (Fig. 1A) .
By activity measurements or by Western blot analysis, we were unable to detect any calcium-independent PLA 2 activity or iPLA 2 protein in platelet homogenate or subcellular fractions thereof (data not shown).
3.4.
Effect of CB52 on intracellular Ca 2+ concentrations
Since Ca 2+ is known to induce cytosol-to-membrane translocation of cPLA 2 -a in many cell types, we investigated the effects of Ca 2+ -chelation on eicosanoid formation by using EGTA and the intracellular Ca 2+ -chelator BAPTA-AM. Platelets were treated with 2 mM EGTA or EGTA and 10 mM BAPTA-AM and thereafter stimulated with CB52. The formation of 12-HETE and 12-HHT increased significantly after treatment of platelets with EGTA/BAPTA-AM as compared to platelets incubated in the presence of 1 mM extracellular Ca 2+ (Fig. 4) . This was surprising since BAPTA-AM previously has been demonstrated to suppress calciumdependent release of arachidonic acid from human platelets [61] . However, several reports describe PCB-induced arachidonic acid release to only be marginally or unaffected by chelation of both extra-and intra-cellular calcium [39, 40, 43, 44, 47] . To more thoroughly investigate the role of Ca 2+ in CB52-induced cPLA 2 -a cytosol-to-membrane translocation, intracellular Ca 2+ changes were measured using Fura2-AM.
Platelets loaded with Fura2 were treated either with vehicle, CB52 or the calcium ionophore ionomycin. Fig. 5 demonstrates representative traces of one such experiment from platelets incubated in the presence of 1 mM extracellular CaCl 2 . CB52 did not induce a significant increase in the fluorescence ratio (Fig. 5, trace A) , indicating that CB52 did not induce an increase in intracellular Ca 2+ . For comparison, the traces of ionomycin or vehicle-treated platelets are also shown (Fig. 5, traces B and C) . 
3.5.
Effects of anti-estrogens on CB52-induced eicosanoid synthesis
In order to determine the mechanism behind CB52-induced arachidonic acid release in human platelets, experiments were designed to investigate whether CB52 could function as a structural analogue of human hormones. It is a well-known fact that PCBs can mimic hormones such as steroids and their reactivity can be expressed in terms of estrogen equivalents [31] . The binding of PCBs to sites distinct from nuclear receptors such as the estrogen receptor and the Ahreceptor, could mediate arachidonic acid release in human platelets. Indeed, the estrogen-antagonist tamoxifen has been reported to decrease the amount of cPLA 2 -a associated with membranes independent of the estrogen receptor [62] . Thus, 17b-estradiol and two anti-estrogens, tamoxifen and nafoxidin, were selected for this study. As depicted in Fig. 6 , platelets pre-treated with tamoxifen or nafoxidin showed a dose-dependent inhibition of CB52 induced 12-HETE formation. Results for 12-HHT are not included in Fig. 6 , due to inhibition of tamoxifen and nafoxidin on the COX/TXA 2 pathways in the broken cell assay. On the other hand, no inhibitory effect was observed for nafoxidin or tamoxifen on the 12-lipoxygenase activity in the broken cell assay (data not shown).
17b-estradiol had no effect on 12-HETE formation in intact platelets (Fig. 6) . Furthermore, preincubation of platelets with dexamethasone (10 mM) for 20 min did not inhibit CB52-induced 12-HETE or 12-HHT formation (data not shown).
To investigate if the estrogen-antagonist nafoxidin or 17b-estradiol could affect the release of arachidonic acid, direct measurement of arachidonic acid release was performed by using platelets labeled with [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-arachidonic acid as described in Section 2. Nafoxidin inhibited CB52-induced release of arachidonic acid from intact platelets by 67.7 AE 16.5% (data is mean AE S.D. from one experiment performed in triplicate). 17b-estradiol at 10 mM had no effect on the release of arachidonic acid from intact platelets (data not shown).
It has been reported that tamoxifen can reduce the amount of cPLA 2 -a associated with membranes [62] . To investigate this in platelets, we examined the effects of both tamoxifen and nafoxidin on cPLA 2 -a activity in an in vitro cPLA 2 C]-arachidonic acid/mg protein, respectively (data is mean AE range from two experiments performed in duplicates). In summary, these results suggest that nafoxidin and tamoxifen impair CB52-induced arachidonic acid release without inhibiting cPLA 2 -a.
CB52 does not induce aggregation of human platelets
The large induction of 12-HHT formation after incubation of platelets with CB52 suggested that PCBs could induce platelet aggregation due to the formation of TXA 2 . Platelets resuspended in PBS were placed in the aggregometer and stimulated with the indicated reagent for up to 10 min at 37 8C with constant stirring. and 12-HHT as those indicated in Table 1 (data not shown). Similar results were obtained for 10 min incubations. For comparison, platelets stimulated with 1 mM calcium ionophore A23187 did aggregate as shown in Fig. 7, (trace B) . Interestingly, preincubation of platelets with 35 mM CB52 for 10 min at 37 8C before addition of A23187 reduced the aggregation by only approximately 30% (Fig. 7 , trace C). This indicated that platelets incubated with CB52 for 10 min still could respond to stimuli that induce aggregation.
Discussion
We report, herein, that low-chlorinated PCBs activate cPLA 2 -a, leading to arachidonic acid release and eicosanoid formation in human platelets. The PCB-induced release of arachidonic acid was clearly structure-dependent since CB118 or CB153 did not induce as much arachidonic acid release or eicosanoid synthesis as CB47 or CB52 (Table 1 ). This indicates that the effect of PCBs on arachidonic acid release is not due to a general disturbance of the membranes, but rather due to a specific activation. Furthermore, we demonstrate that CB52 induces phosphorylation and cytosol-to-membrane translocation of cPLA 2 -a, independent of a rise in intracellular calcium. It is by now a well-known fact that calcium can promote cytosol-to-membrane translocation of cPLA 2 -a. However, several papers describe a calcium-independent cytosolto-membrane translocation of cPLA 2 -a [19, 21, 63] . It has been suggested that cPLA 2 -a can undergo interfacial binding by two different modes, i.e. calcium-dependent binding via the C2 domain [13] [14] [15] or calcium-independent binding through a phospholipid-binding region in the catalytic domain [21, 19] . Furthermore, agents such as okadaic acid and phorbol myristate acetate (PMA) induces arachidonic acid release without increasing intracellular calcium concentration [22] . Also, it was reported earlier that thrombin-stimulated platelets produced more TXA 2 in the absence of extracellular calcium [64] . Taken together, these lines of evidence suggest an alternative mechanism for cPLA 2 -a cytosol-to-membrane translocation, which is independent of increased calcium concentrations. It remains to be investigated if the observed phosphorylation of cPLA 2 -a after PCB-treatment (Fig. 5) contributes to the calcium-independent cytosol-to-membrane translocation.
A structure-activity relationship among PCB congeners demonstrated a mechanism through which these compounds could affect calcium signaling in neuronal cells by binding to the ryanodine receptor in the endoplasmatic reticulum. This binding leads to release of Ca 2+ from the endoplasmatic reticulum [65] . However, that mechanism is not likely the cause for the observed effects of PCBs on platelets since no increase in intracellular Ca 2+ could be observed. Also, we found that ruthenium red, an inhibitor of PCB-induced Ca 2+ -release mediated via the ryanodine receptor, had no effect on CB52-induced 12-HETE or 12-HHT formation (data not shown).
The mechanism behind PCB-induced eicosanoid formation in human platelets involves cytosol-to-membrane translocation of cPLA 2 -a and possibly also phosphorylation of the enzyme. It has previously been reported that PCBs can induce cytosol-to-membrane translocation of cPLA 2 -a in rat renal tubular cells after exposure of the cells to PCBs for 60 min [66] . This effect was partially dependent on de novo protein synthesis, suggesting a mechanism involving increased synthesis of cPLA 2 -a. However, the signaling pathway leading to the activation of cPLA 2 -a in human platelets is unknown. Since platelets lack a nucleus, it is unlikely that the observed effects of PCBs are mediated via de novo protein synthesis. Nevertheless, non-genomic effects could account for some of the observed effects of PCBs on arachidonic acid release [67] . Platelets have been found to possess both estrogen-receptor a and b [68] . The lack of effect of 17b-estradiol on arachidonic acid release observed in this report is in line with previous reported findings [69] and suggests that the estrogen receptors are not involved in PCB-induced arachidonic acid release. Also, the estrogen-like activities of CB47, CB52, CB118 and CB153 [70, 71] does not correlate with their ability to induce eicosanoid synthesis and arachidonic acid release in platelets. Thus, the effects observed for anti-estrogens on CB52-induced eicosanoid formation suggest that PCBs might activate cPLA 2 -a by binding to a binding site distinct from the estrogen receptors. A high-affinity binding site for tamoxifen, distinct from the estrogen receptor has indeed been described [72] . If this binding site, or a similar is involved in PCB-induced eicosanoid formation in platelets remains to be investigated. Tamoxifen has been reported to decrease the amount of cPLA 2 -a associated with membranes in A549 lung adenocarcinoma cell line [62] . However, we were unable to detect any inhibitory effects of tamoxifen or nafoxidin on platelet cPLA 2 a activity in an in vitro assay. This suggests that the effects observed for tamoxifen on human A549 cells and platelets is mediated through different mechanisms. Tamoxifen is currently one of the most commonly used drugs for endocrine therapy of breast cancer. The possibility that the inhibition of eicosanoid synthesis and arachidonic acid release by antiestrogens observed in this report is involved in the chemoprevention of breast cancer remains to be investigated. Interestingly, the 12-LO pathway has been suggested to play a key role in breast cancer cell growth as well as in prostate tumor motility [73, 74] .
In conclusion, low-chlorinated PCBs activate cPLA 2 -a in human platelets leading to eicosanoid formation. Interestingly, cPLA 2 -a play important roles in tissues or cells known to also be affected by PCB, such as reproductive and brain tissue as well as blood cells. PCBs might be useful tools in further studies of hormonal-induced arachidonic acid release.
